Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-07-13Clinical Trial Update: Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) [Phase 2]
A Phase 2 trial evaluating the investigational drug A6 for chronic lymphocytic leukemia and small lymphocytic lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2016-06-28Clinical Trial Update: Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of Akt inhibitor MK2206 combined with bendamustine and rituximab in relapsed CLL or small lymphocytic lymphoma has completed…
-
FDA approval · 2016-06-23FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) submitted by Teva Pharmaceuticals USA, Inc., indicating reg…
-
CLINICAL_TRIALS trial_result · 2016-05-09Clinical Trial Update: Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) [Phase 1]
Phase 1 study of carfilzomib in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or prolymphocytic leukemia has compl…
-
CLINICAL_TRIALS trial_result · 2016-05-04Clinical Trial Update: Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL [Phase 3]
Phase 3 open-label trial comparing ibrutinib to chlorambucil in patients 65 years or older with treatment-naive chronic lymphocytic leukemia…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-04-19Clinical Trial Update: Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 1]
A completed Phase 1 safety study evaluating CC-292 in combination with Rituximab in patients with chronic lymphocytic leukemia and/or small …
-
FDA approval · 2016-04-11FDA Approved: VENCLEXTA — Original Application (AbbVie Inc.)
FDA approved the original application for VENCLEXTA (venetoclax) by AbbVie. The approval covers the treatment of chronic lymphocytic leukemi…
-
FDA approval · 2016-03-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) filed by Pharmacyclics LLC. The document indicates FDA action on a supplem…
-
EMA safety_alert · 2016-03-11EMA reviews cancer medicine Zydelig
The EMA reviews the cancer medicine Zydelig (idelalisib) for potential safety concerns and evaluates available data.
-
CLINICAL_TRIALS withdrawal · 2016-03-02Clinical Trial Update: Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1]
Phase 1 trial of MT-3724 for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma has been withdrawn; no results are reported…
-
CLINICAL_TRIALS trial_result · 2016-01-18Clinical Trial Update: Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) [Phase 2]
A Phase I/II trial of the gold compound auranofin in chronic lymphocytic leukemia and related lymphoid conditions has completed its Phase 2 …
-
CLINICAL_TRIALS trial_result · 2015-12-17Clinical Trial Update: Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a radiolabeled monoclonal antibody with rituximab, with/without filgrastim and interleukin-11, in relapsed or r…
-
CLINICAL_TRIALS trial_result · 2015-12-15Clinical Trial Update: Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Phase 2]
Phase 2 trial evaluating the combination of ofatumumab and bendamustine in patients with previously treated chronic lymphocytic leukemia and…
-
CLINICAL_TRIALS trial_result · 2015-12-04Clinical Trial Update: Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of obatoclax with bortezomib in adults with aggressive relapsed or recurrent non-Hodgkin lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2015-11-26Clinical Trial Update: Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial of lenalidomide plus rituximab as maintenance therapy for adult B-cell non-Hodgkin lymphoma is noted as terminated.
-
CLINICAL_TRIALS trial_result · 2015-11-20Clinical Trial Update: Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [Phase 2]
Phase 2 study update for Memgen's Ad-ISF35 cancer vaccine in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma; the trial was term…
-
CLINICAL_TRIALS trial_result · 2015-11-20Clinical Trial Update: Study of Repeat Intranodal Injections of Ad-ISF35 [Phase 2]
Phase 2 study of repeat intranodal injections of Ad-ISF35 in various non-Hodgkin lymphomas was terminated; results were posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-11-11Clinical Trial Update: Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1]
This is a Phase 1 clinical trial update reporting results for Cyclophosphamide, Alvocidib, and Rituximab in high-risk B-cell chronic lymphoc…
-
FDA approval · 2015-11-05FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS trial_result · 2015-11-04Clinical Trial Update: Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia [Phase 1]
Phase 1 trial of Alvespimycin hydrochloride in relapsed/refractory B-cell chronic lymphocytic leukemia, prolymphocytic leukemia, and small l…
-
CLINICAL_TRIALS trial_result · 2015-10-19Clinical Trial Update: Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma [Phase 1]
Phase 1 study of GS-9901 in adults with relapsed or refractory follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, or…
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 3]
Phase 3 trial updating results for ibrutinib versus ofatumumab in relapsed/refractory CLL and SLL; results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-08-27Clinical Trial Update: Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating lenalidomide in combination with rituximab for chronic lymphocytic leukemia and small lymphocytic lymphoma…
-
FDA approval · 2015-07-08FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS trial_result · 2015-07-02Clinical Trial Update: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery [Phase 1]
Phase 1 study sponsored by the National Cancer Institute evaluating dasatinib in patients with metastatic or unresectable solid tumors and l…